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Abstract
Background: Critical illness, mediated by trauma or sepsis, can lead to physiological changes that alter the
pharmacokinetics of antibiotics and may result in sub-therapeutic concentrations at the sites of infection. The first
aim of this project is to identify the clinical characteristics of critically ill patients with significant trauma that have
been recently admitted to ICU that may predict the dosing requirements for the antibiotic, cefazolin. The second
aim of this is to identify the clinical characteristics of critically ill patients with sepsis that may predict the dosing
requirements for the combination antibiotic, piperacillin-tazobactam.
Methods/Design: This is an observational pharmacokinetic study of patients with trauma (cefazolin) or with sepsis
(piperacillin-tazobactam). Participants will have samples from blood and urine, collected at different intervals.
Patients will also have a microdialysis catheter inserted into subcutaneous tissue to measure interstitial fluid
penetration of the antibiotic. Participants will be administered sinistrin, indocyanine green and sodium bromide as
well as have cardiac output monitoring performed and tetrapolar bioimpedance to determine physiological
changes resulting from pathology. Analysis of samples will be performed using validated liquid chromatography
tandem mass-spectrometry. Pharmacokinetic analysis will be performed using non-linear mixed effects modeling to
determine individual and population pharmacokinetic parameters of antibiotics.
Discussion: The study will describe cefazolin and piperacillin-tazobactam concentrations in plasma and the
interstitial fluid of tissues in trauma and sepsis patients respectively. The results of this study will guide clinicians to
effectively dose these antibiotics in order to maximize the concentration of antibiotics in the interstitial fluid of
tissues.
Background
The incidence of infection in critically ill patients, suf-
fered before or following admission to ICU, is increas-
ing. In Australia and New Zealand, 12% of admissions
to intensive care units (ICU’s) are for severe sepsis [1].
Despite advances in critical care medicine, 27% of these
patients will die [1]. Improved antibiotic therapy has
been proposed as a mechanism to improve outcome for
septic patients [2,3], although the achievement of this
depends on both the timely selection of an appropriate
antibiotic and on using an appropriate dose so as to
obtain appropriate antibiotic concentrations at the site
of infection.
Data describing the likely benefits of appropriate dos-
ing of antibiotics remains sparse [4-7]. The antibiotic
dosing schedule for a trauma patient admitted to ICU is
presently poorly defined and largely empiric. Dosing
schedules rely largely on data obtained in non-critically
ill patients and there is increasing evidence that describes
how such an approach is likely to result in inadequate
therapy [2,8].
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innate immune system with the release of cytokines,
interleukins and other mediators of inflammation [9].
This response may be localised or systemic; if systemic
it is referred to as the systemic inflammatory response
syndrome (SIRS). Sepsis is then defined as SIRS in the
presence of a suspected or documented infection [10].
Many pathological processes (such as trauma, pancrea-
titis, burns and major surgery) can produce a SIRS
response, leading to sepsis, if an infection is super-
imposed. The hemodynamic changes common to the
SIRS response, regardless of the initiating insult, include
a low systemic vascular resistance and a high cardiac
output described as a hyperdynamic circulation [11].
This hyperdynamic circulatory SIRS response has been
demonstrated to have an effect on the creatinine clear-
ance (CLCR) [12]. The magnitude of this effect is such
that CLCR can be increased by 50-100% [13]. This
increase in CLCR can occur in the presence of a normal
serum creatinine concentration [14]. Identification of
these patients based on laboratory creatinine concentra-
t i o n si st h u sd i f f i c u l t .I nf a c t ,i th a sb e e nd e m o n s t r a t e d
that an isolated serum creatinine concentration within
the “normal” reference range is an insensitive indicator
of the glomerular filtration rate in the critically ill [15].
The haemodynamic changes, induced by the SIRS
response, may thus lead to altered pharmacokinetics
(PK) through an augmented renal clearance in patients
without significant renal dysfunction [16]. CLCR is an
important determinant in the pharmacokinetics of anti-
biotics in the critically ill [17,18].
A significant concern for clinicians is that the adminis-
tration of standard antibiotic doses in such patients may
result in a sub-therapeutic concentration, leading to sub-
optimal bacterial kill. In trauma patients receiving anti-
biotic prophylaxis, this may increase the risk of sepsis. In
a patient with sepsis this may result in treatment failure
with an increased mortality [2,3,19]. In addition, in both
trauma and septic patients, failure to achieve adequate
concentrations may result in the development of antibio-
tic resistance [20]. As such identification of the physiolo-
gical characteristics of patients with a hyperdynamic
circulation and thus an augmented renal clearance is
poorly described and clinically important.
The optimal measurement of renal function in criti-
cally ill patients is still uncertain [16]. The Cockcroft-
Gault equation is still widely utilized but its application
in critically ill patients has been questioned [15,21-23].
Urinary creatinine collections of 8, 12 and 24 hrs have
been used (with matched serum creatinine concentra-
tions) although this will tend to overestimate GFR at
lower filtration rates. Sinistrin clearance has also been
used to measure GFR due to its unique properties of
limited renal tubular secretion and reabsorption and
may provide insight into the accuracy of other
approaches in critically ill patients [24].
In addition to changes in renal function, trauma and
sepsis may also induce increased capillary leakage, micro-
vascular stasis and the accumulation of peripheral fluid
[11]. Previous studies evaluating antibiotic PK in the pre-
sence of sepsis or trauma have shown the volume of dis-
tribution of hydrophilic antibiotics to be significantly
increased [24-26]. This capillary leak syndrome is well
described in sepsis and to a lesser extent in patients with
major trauma [27-29]. Trauma is further implicated in
altered pharmacokinetics secondary to possible reduced
intravascular volume, massive fluids shifts, and hypopro-
teinemia [3,30]. Hypoproteinemia is well described in
sepsis and critical care [31]. These changes impact on
antibiotic diffusion distance and delivery resulting in
s l o wa n dp o s s i b l ei n c o m p l e t ea n t i b i o t i ct i s s u ep e n e t r a -
tion into infected tissues [3,16,32,33].
A consequence of the physiological changes, seen in
both septic and trauma patients, is that these two sub-
groups of critically ill patients are at risk of significantly
different pharmacokinetic (PK) profiles with respect to
that of non-critically ill patients. As such standard treat-
ment regimens are likely to be ineffective and result in
sub-therapeutic target tissue concentrations.
Currently there is little data to guide the clinician to
predict which patients may have different PKs in the
acute phase of trauma or during sepsis. Furthermore
most studies have examined the total drug concentra-
tions in serum, rather than the pharmacologically active
unbound drug in tissues where most infections occur
[34]. This uncertainty of dosing requirements, in the pre-
sence of data that highlights the importance of appropri-
ate antibiotic therapy, is of critical importance.
The identification of the physiological predictors of
altered PK allows the development of dosing algorithms
that can maximise the target site antibiotic concentra-
tion and reduce treatment failure.
As detailed above there are many causes for potential
altered PK in patients both with sepsis or trauma. There
is some overlap between the physiological pathways that
cause these alterations in PK. However, we propose to
study sepsis and trauma patients in separate groups,
with the sepsis group receiving treatment with piperacil-
lin-tazobactam and the trauma group receiving prophy-
laxis with cefazolin.
Piperacillin-tazobactam is a combination of a semisyn-
thetic penicillin and b-lactamase inhibitor that is com-
monly used for empiric therapy of sepsis. Cefazolin is a
narrower spectrum first generation cephalosporin anti-
biotic commonly used as prophylaxis in critically ill
patients with traumatic injuries. Little data exists to con-
firm the appropriateness of dosing of these important
antibiotics for critically ill patients. There is no data
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kinetics of these antibiotics and the physiological
changes that occur in patients that have sepsis or signifi-
cant traumatic injuries.
Aims
The first aim of this project is to identify the clinical
characteristics of critically ill patients with significant
trauma, that have been recently admitted to ICU, that
may predict the dosing requirements for the antibiotic,
cefazolin.
The second aim of this is to identify the clinical char-
acteristics of critically ill patients with sepsis that may
predict the dosing requirements for the combination
antibiotic, piperacillin-tazobactam.
Our approach is to accurately describe the patient’s
altered physiology and develop physiologically-based
pharmacokinetic (PBPK) models that may describe
plasma and tissue cefazolin and piperacillin-tazobactam
concentrations for each of these patient groups.
Methods/Design
Study design
This is an open-labelled pharmacokinetic study. Samples
of blood, tissue microdialysate and urine will be col-
lected from participants being treated in the ICU of the
Royal Brisbane and Women’s Hospital (RBWH),
Queensland, Australia and the Princess Alexandra Hos-
pital (PAH), Queensland, Australia for sepsis or major
trauma.
Setting
The clinical study will be performed in the ICU at
RBWH and the PAH, which have approximately 4000
patients admitted annually. This work will be done in
collaboration with the Burns, Trauma and Critical Care
Research Centre and the Therapeutics Research Centre,
School of Medicine, The University of Queensland.
Identification of Eligible Patients
Participants would need to meet the inclusion and
exclusion criteria to be enrolled. Informed consent will
be obtained from each patient or a legally authorised
representative to participate in the study.
Inclusion criteria
￿ Age of between 18 years and 80 years.
￿ Clinical indication for therapy with cefazolin for
trauma patients or piperacillin-tazobactam after
diagnosis of sepsis where sepsis is defined as:
○ Clinical suspicion of infection and/or positive
culture results
○ SIRS as defined by two or more of the follow-
ing [10]:
▪ Core temperature <36°C or >38°C
▪ Tachycardia as defined by a heart rate >90
beats per minute
▪ Tachypnoea as defined by a respiratory rate
greater than 20 breaths per minute OR a
PaCO2 less than 32 mmHg during sponta-
neous breathing OR the requirement for
mechanical ventilation.
▪ A white blood cell count >12 × 10
9/L or
<4 × 10
9/L OR greater than 10% immature
(band) forms.
￿ Renal function as defined by:
○ Serum creatinine concentration <170 μmol/L
￿ An arterial line in situ
￿ Written informed consent obtained
Exclusion criteria
Participants will be excluded if they have pre-existing
renal impairment (serum creatinine concentration
≥171 μmol/L) or if they have a history of allergy to the
study antibiotic or iodine.
Participants
Participants will be recruited into two separate groups:
1. Trauma patients (n = 30) receiving cefazolin; and
2. Sepsis patients (n = 50) receiving piperacillin-
tazobactam.
Drug dosing
Antibiotic administration will only occur in patients where
the treating clinician has deemed a clinical need for the
study antibiotic. Administration will occur in line with the
manufacturer’s guidelines for each product. Cefazolin will
be administered in 20 ml 0.9% sodium chloride by intrave-
nous infusion via a central venous catheter over 5-minutes
and piperacillin-tazobactam will be administered in 50 ml
0.9% sodium chloride by intravenous infusion via a central
venous catheter over 20-minutes.
Other marker compounds will also be administered to
assess the physiology of the patient at the time of anti-
biotic administration.
Indocyanine green (ICG) - Pulsion 0.5 mg/kg (maxi-
mum dose 50 mg) will be administered to provide a
measure of plasma volume, an indication of hepatic
function and the distribution kinetics of highly bound
solutes. Plasma volume will be obtained from the final
ICG concentration [35]. The ICG will be administered
as a rapid bolus via central venous line 10 min prior to
the start of the antibiotic infusion. ICG non-invasive
oximetry measurements will be taken over a period of
7 min.
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administered intravenously to measure extracellular
fluid fluctuations [36]. It will be administered as a slow
bolus over 3 min. For cefazolin, sodium bromide will be
administered starting 2 min after the initiation of the
antibiotic infusion and for piperacillin-tazobactam,
it will be administered for the final 3-minutes of the
20-minute antibiotic infusion [37].
Sinistrin 2500 mg (Inutest
R, Laevosan, Linz, Austria)
will be given as a bolus over 30 seconds to help deter-
mine renal function (GFR). For cefazolin, sinistrin will
be administered over the final 30-seconds of the antibio-
tic infusion and for piperacillin-tazobactam, it will be
administered over the final 30-seconds of the 20-minute
antibiotic infusion [38].
Sample collection
Sampling will occur during one 6-hour dosing interval
for each patient.
Blood Samples
Six blood samples will be taken for each antibiotic.
Piperacillin-tazobactam (infused over 20 min) - the
first sample will be taken 1 minute prior to start of the
infusion and then at 20 min (end of infusion), 40 min,
60 min, 210 min and 360 min respectively post com-
mencement of the infusion.
Cephazolin (infused over 5 min). The first sample will
be taken 1 minute prior to the infusion of the antibiotic
a n dt h e na t5m i n( e n do fi n f u s i o n ) ,2 0m i n ,6 0m i n ,
210 min and 360 min respectively post commencement
of the infusion.
Microdialysis Samples
Following insertion of a microdialysis catheter (CMA 60,
20 kDa dialysis window, Global Scientific, Sweden) sub-
cutaneously by an experienced clinician, fourteen sam-
ples will be collected over the course of the antibiotic
dosing interval. The catheter will be perfused with a solu-
tion of 0.9% sodium chloride and cefalotin (10 mg/L)
which acts as a marker antibiotic of similar molecular
size and physicochemical properties to the study antibio-
tics. Cefalotin will assist in the determination of the rate
of movement of molecules across the dialysis membrane
according to the retrodialysis method [39,40]. The first
microdialysis sample is taken 1 min prior to the start of
the antibiotic infusion with repeat measurements taken
at 20 min, 40 min, 60 min, 90 min, 120 min, 150 min,
180 min, 210 min, 240 min, 270 min, 300 min, 330 min,
and at 360 min respectively following which the micro-
dialysis catheter will be removed.
Urine Samples
Urine samples for creatinine clearance will be collected as
previously described according to the urinary collection
clearance method [41]. Urine collection will start at the
time of initiation of the antibiotic infusion. At 2 hours,
4 hours and 6 hours the urine will be collected with a 5 ml
aliquot taken for quantification of the rate and amount of
antibiotic excreted in that particular 2 hour time period.
After the 6-hour sample, a subsequent 8-hour collection
will commence providing four urinary creatinine clearance
measures over a 14-hour period.
Tetrapolar Bioimpedance
An experienced clinician will perform tetrapolar bioim-
pedance on two occasions during the study. The first
measurement occurring 20 minutes prior to the antibio-
tic dose and then repeated six and a half hours post
initiation of the infusion. The results will be used for
measuring the fat free mass [42] of the patient and
detecting altered fluid status (e.g. variations in extracel-
lular water) over the study period.
Cardiac Output
Pulse contour arterial waveform analysis will be used to
measure cardiac output and other derived haemody-
namic measurements utilizing the FloTrac/Vigileo™ sys-
tem (Edwards Lifesciences, Irvine, CA, USA). Cardiac
output results will be confirmed using an UltraSonic
Cardiac Output Monitor (The USCOM ultrasonic CO
monitor USCOM Pty, Coffs Harbour, NSW, Australia).
These measurements will be made simultaneously at
three times post the initiation of the antibiotic infusion
(0 minutes, 180 minutes and 300 minutes).
Sample handling and storage
Blood samples that are collected will immediately be
placed on ice and centrifuged within 60-minutes of sam-
pling at 3000 rpm for 10-minutes and stored at -80°C
until assay. Microdialysis and urine samples will be
stored at -80°C until assay.
Sample analysis
Assays of all samples will occur, within 30-days of col-
lection, at the Therapeutics Research Centre of The
University of Queensland.
Blood, urine and microdialysis samples will be ana-
lysed using validated liquid chromatography-tandem-
mass spectrometry (LC-MS/MS) analytical assays.
Blood plasma protein and albumin concentrations will
be measured. The unbound fraction of antibiotic in
plasma will be determined using ultracentrifugation
(12000 rpm for 20-minutes) through 3 kDa nominal
cut-off membrane devices (Amicon
® YM30, Millopore
Corporation, Billerica, MA).
ICG, sodium bromide and sinistrin concentrations will
all be measured using validated High-Performance-Liquid-
Chromatography (HPLC) assays. ICG concentration clear-
ance will also be assessed by non-invasive oximetry
(LiMon - Pulsion Medical Systems) Non-invasive tetrapo-
lar bioimpedance will be compared with measured sodium
bromide concentrations.
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collection will be compared with other measures of
renal function, including results from the sinistrin analy-
sis (glomerular filtration) and creatinine clearance deter-
mination using the Cockroft-Gault formula [43].
Analysis of the 5 ml urine aliquots for antibiotic clear-
ance will be performed using validated LC-MS/MS
assays and will determine the rate and amount of anti-
biotic excreted in urine.
Data collection
Additional data will be obtained from the medical
record and will include:
1. Participant demographics including age, gender,
height, allergies, co-morbidities;
2. Clinical details (admission diagnosis, progress and
outcome);
3. Measures of illness severity, including Acute Phy-
siology and Chronic Health Evaluation (APACHE) II
score on admission [44];
4. A daily Sepsis Organ Failure Assessment (SOFA)
score [45];
5. Revised Trauma Score (RTS) [46];
6. A tissue penetration and perfusion score consist-
ing of oxygen saturation (%), serum lactate concen-
tration (mmol/L) and noradrenaline dose (mcg/kg/
min) will be taken at the time of the antibiotic infu-
sion [47];
7. Microbiology results - Gram stain, culture and
antimicrobial sensitivities of blood cultures or other
culture sites following admission to hospital;
8. Laboratory investigations - full blood count,
serum biochemistry, coagulation profile, liver func-
tion tests and arterial blood gas measurements.
Statistical considerations
It is anticipated that a minimum of 30 patients with
data-rich sampling will be required to develop a phar-
macokinetic model defining at least 3 predictors. The
sample size is based on a power of 80%, a level of signif-
icance of 5%, multiple regression analysis with 3 predic-
tor variables and a R-square (proportion of variation
explained) of 30% [48].
Data analysis
Pharmacokinetic modelling of antibiotic distribution and
clearances will be performed and compared, where pos-
sible, to previously published pharmacokinetic data from
healthy volunteers and other non-critically ill patient
groups. The results of sample analysis will be analysed
using a non-linear mixed effects modelling approach
(NONMEM, GloboMax LLC, Hanover, MD, USA). The
aim of this process will be to develop a baseline popula-
tion physiologically-based-pharmacokinetic (PBPK)
model for each antibiotic assuming a re-circulatory
PBPK-pharmacodynamic (PBPKPD) model [49,50].
NONMEM will mainly be used to model between sub-
ject variability and within subject variability in simulta-
n e o u s l ym o d e l l i n gs p a r s ed a t af r o mm u l t i p l ep a t i e n t s
with a classical compartmental approach. Each of the
factors that are identified to affect antibiotic pharmaco-
kinetics will then be incorporated into the model to
help describe the between subject variability and within
subject variability, defining, where possible, the extent a
patient’s pharmacokinetics changes during critical ill-
ness. Incorporation of all variables will be used to
develop a user-friendly antibiotic dosing algorithm.
The influence of demographic and clinical covariates
will be tested in the model. The model will simulate
antibiotic pharmacokinetics for different dosing sche-
dules to predict the best dosing recommendations for
sepsis patients receiving piperacillin-tazobactam and
trauma patients receiving cefazolin.
Ethical considerations
The Human Research and Ethics Committee of the
RBWH (2007/188). Princess Alexandra Hospital and the
Medical Research Ethics Committee of the University of
Queensland (2008000449) have approved this study.
Withdrawal from Study
Participants may withdraw from the study at anytime
without prejudice, as documented and explained at the
time of consenting.
Discussion
It is becoming increasingly evident that the dosing
requirements for antibiotics in critically ill patients are
different to non-critically ill patients. The pharmacoki-
netics in critically ill patients is affected by changes in
haemodynamic parameters, hypoproteinemia, microvas-
cular flow and capillary leak. This is due, in part, to the
hyperdynamic circulation and augmented renal clearance
induced by the SIRS response in both trauma and sepsis,
resulting in increased GFR. The altered tissue physiology
found in sepsis and trauma with increased capillary leak-
age and blood flow stasis may lead to altered volumes of
distribution and slow antibiotic penetration. Trauma and
sepsis are further implicated in altered pharmacokinetics
secondary to possible reduced intravascular volume, mas-
sive fluids shifts, and hypoproteinemia. These two speci-
fic groups of patients are therefore at risk of altered
pharmacokinetics and the potential for antibiotic under-
dosing demands further investigation.
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Inappropriate antibiotic administration can lead to selec-
tion of resistant organisms and failure of therapy with
increased mortality [2,3]. Identification of the physiolo-
gical characteristics that may predict an altered pharma-
cokinetic profile will enable optimised dosing in these
individuals. The proposed study will identify parameters
instructive of the need for altered antibiotic doses to
ensure therapeutic concentrations in both plasma and in
the interstitial fluid of tissues.
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